Campbell Becher
QLGNAbout Campbell Becher
Campbell Becher is President of Qualigen Therapeutics (QLGN), appointed September 25, 2024, amid leadership transitions; he later resigned his board seat on October 1, 2025 but remains President . He is 53 and brings 20+ years in capital markets and operating roles, including CEO of IberAmerican Lithium since September 2023, President of Orchid Capital Partners since 2014, and former Founder/CEO of Byron Capital Markets (2008–2014), with prior Managing Director experience at Haywood Securities . Company-wide pay-for-performance context shows cumulative TSR declined from $38.21 in 2021 to $4.29 in 2022 and $1.83 in 2023, with net losses of $17.9M (2021), $18.6M (2022), and $13.4M (2023) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| IberAmerican Lithium | Chief Executive Officer | Sep 2023–present | Leads lithium-focused growth strategy |
| Orchid Capital Partners Corp. | President | 2014–present | Investment and advisory leadership |
| Byron Capital Markets | Founder & CEO | 2008–2014 | Built electric metals investment bank; sponsored Electric Metals and Industrial Minerals lithium conferences |
| Haywood Securities Inc. | Managing Director | Not disclosed | Senior capital markets leadership |
External Roles
| Organization | Role | Years |
|---|---|---|
| Royal Helium Ltd. | Board Member | Not disclosed |
| Strategic Minerals Europe Corp. | Board Member | Not disclosed |
Fixed Compensation
- No individual employment agreement or officer cash pay terms for Becher are disclosed in QLGN filings reviewed; the Board did disclose a consulting fee for Interim CEO/CFO Kevin Richardson of $4,500 per week (context for executive cash practices) .
Performance Compensation
- Company adopted a 2025 Equity Incentive Plan with a share pool equal to 20% of post-Offering common stock and a 10% annual “evergreen” through 2046; awards can include options, RSUs, SARs, and performance awards . Plan performance measures can include revenues, EBITDA, EBITDA margin, operating income, total stockholder return, cash flow, gross margin, net income, ROE/ROA, market share, price-to-earnings growth, and strategic milestones (e.g., product launches, financings, M&A), with change-in-control provisions allowing acceleration/substitution/cash-out at Board discretion . Individual award metrics, weights, targets, and payouts for Becher are not disclosed .
Equity Ownership & Alignment
| Item | Detail |
|---|---|
| Beneficial Ownership | Less than 1% of common stock as of September 22, 2025 |
| Shares Outstanding (basis for table) | 2,659,133 common shares outstanding as of September 22, 2025 (per DEF 14A table) |
- No disclosure of Becher’s exact share count, option holdings, vesting schedules, or pledging; company policy prohibits hedging or offsetting against compensatory securities and includes a clawback policy for erroneously awarded incentive comp .
Employment Terms
| Term | Detail |
|---|---|
| Appointment | Appointed President on September 25, 2024 |
| Board Tenure | Director during 2024; resigned from Board October 1, 2025; remains President |
| Advisory/Other Agreements | In September 2025 transaction documents, “Advisory Agreements” were defined for Cody Price, Campbell Becher, and Robert Lim (terms not disclosed) |
| Change-in-Control (Plan-level) | 2025 Equity Plan permits acceleration, substitution, or cash-out of awards upon change-in-control at Board discretion |
| Clawback & Hedging Policies | Company has formal clawback policy and prohibits hedging/offsetting by employees/directors |
Board Governance
| Area | Detail |
|---|---|
| Committee roles (2024) | Compensation Committee Chair (Becher), with members Korenberg and Lim |
| Committee roles (2024) | Nominating & Corporate Governance Committee member (Lim Chair; members Becher and Price) |
| 2025 Board transition | Becher resigned from Board Oct 1, 2025 as part of governance and financing changes; remained President |
| Later committee changes | Audit Committee leadership reassignments in 2025 (context for governance flux) |
Director Compensation (Historical program; not specific to Becher)
| Component | Amount | Notes |
|---|---|---|
| Annual retainer (non-employee directors) | $35,000 (cash) | 2023 program; 20% temporary reduction from Jan 13, 2023; reinstated Aug 1, 2023 |
| Committee Chair fees | $15,000 (Audit), $10,000 (other) | 2023 program |
| Committee member fees | $7,500 (Audit), $5,000 (other) | 2023 program |
Performance & Track Record (Company context)
| Metric | 2021 | 2022 | 2023 |
|---|---|---|---|
| Value of $100 investment (TSR) | $38.21 | $4.29 | $1.83 |
| Net Loss Attributable to QLGN (millions) | $(17.9) | $(18.6) | $(13.4) |
- Leadership transitions in September 2024 included CEO and CFO resignations over strategic disagreements, Becher’s appointment as President, and appointment of a new Interim CEO/CFO with consulting compensation terms .
Employment & Contracts (Additional context)
- 2025 financing agreements contemplated board size changes, lead investor director designees, and executive appointments; Board requested resignations of Becher (as director), Lim, and Price with investor designees added, while Becher continued as President .
Investment Implications
- Alignment: Beneficial ownership disclosed as <1%, and no individual award disclosures for Becher create limited transparency on pay-for-performance alignment; reliance on Plan-level metrics and Board discretion for CIC suggests flexibility but less visibility for investors .
- Retention risk: Absence of disclosed officer pay terms (salary, bonus, equity vesting) and advisory constructs around 2025 financing complicate assessment of retention incentives; governance flux (board resignations/reconfigurations) adds uncertainty .
- Trading signals: Lack of disclosed option/RSU schedules and insider transactions hampers view on potential selling pressure; macro context shows historical TSR compression and net losses, with 2025 Plan aiming to re-align incentives to performance metrics (revenues, EBITDA, TSR) .
- Governance: Becher’s 2024 roles as Compensation Chair and later resignation from the Board (remaining President) reflect shifting oversight and investor-led governance changes; robust D&O indemnification, clawback, and anti-hedging policies exist at the company level .